PitchSend

Popular
Blog
Companies
Finance
Technology
Banking
Information Technology
Oil and Energy
Internet
Mining and Metals
Communications
Real Estate
Biotechnology
Automotive
Medical
Retail
Energy
Investor Presentaiton slide image

Investor Presentaiton

Dual Indications - Two Phlla Trials Final Results Anticipated in 2022 & 2023 Indication Enrollment Treatment duration Site location ONENESS Atopic Dermatitis (AD) 99 16 weeks US Final data and CSR anticipated in H1 2022 Indication Enrollment Treatment duration Site location Allergic Asthma (AA) 100 36 weeks (FB825 vs Placebo: 50 vs 50) Trial completion in H1 2023 (AA is Sponsored by Microbio Shanghai) Taiwan |21
View entire presentation

Product

HomeSearchAccount

Categories

Finance PresentationsTechnology PresentationsBanking PresentationsInformation Technology PresentationsOil and Energy PresentationsInternet PresentationsMining and Metals PresentationsCommunications PresentationsReal Estate PresentationsBiotechnology PresentationsAutomotive PresentationsMedical PresentationsRetail PresentationsEnergy Presentations

Company

InsightsContactSupport

Legal

Terms of ServicePrivacy Policy

Connect

TwitterLinkedInInstagramYouTube